BEBT-209
BEBT-209 primarily inhibits CDK4 with a potency that is six times greater than CDK6, aiming to reduce the hematological toxicities inherited by broader CDK4/6 inhibitors. Phase II results in metastatic triple-negative breast cancer (mTNBC) patients with prior systemic therapy demonstrate a 43.5% objective response rate (ORR) and 6.7 mo progression-free survival (PFS), outperforming Sacituzumab Govitecan-hziy (SG, 31.0% ORR, 4.8 mo PFS), with comparable adverse events when combined with chemo. We plan to launch a global Phase III trial for mTNBC in 2025.
Copyright ©2018-2022 Guangzhou BeBetter Medicine Technology Co, LTD.粤ICP备18065301号